IDH1 and colorectal carcinoma: Tougeron et al. have not manged to observe IDH1/2 in CRC patients (Tougeron et al., 2016), while Whitehall et al. have underlined that these mutation are present in correspondence to the CpG island methylator phenotype and in the presence of BRAF mutations (Whitehall et al., 2014).